

Continuation of preparations for the ministerial segment of the sixty-second session of the Commission on Narcotic Drugs, to be held in 2019, during the intersessional period of its sixty-first session

3rd inters	3rd intersessional meeting:				
Time and Venue	Thematic focus	Format			
25-28 September (Board Room C)	Day I  Demand reduction and related measures <sup>1</sup> , including <sup>2</sup> :  Reducing drug abuse and dependence through a comprehensive approach; <sup>3</sup> Prevention of drug abuse; <sup>4</sup> Treatment of drug use disorders, rehabilitation, recovery and social reintegration; prevention, treatment and care of HIV/AIDS, viral hepatitis and other blood-borne infectious diseases; <sup>5</sup> Eliminating or reducing significantly and measurably the illicit demand for narcotic drugs and psychotropic substances; and drug-related health and social risks; <sup>6</sup>	THEMATIC SEGMENT:  - Introductory presentations by UNODC and other relevant UN entities (45 min.)  - Interactive discussion7 (5 minutes each)  - Interactive debate			
	Day II  Ensuring the availability of and access to controlled substances exclusively for medical and scientific purposes, while preventing their diversion; <sup>8</sup>	THEMATIC SEGMENT: - Introductory presentations by UNODC and other relevant UN entities (45 min.) - Interactive discussion (5 minutes each) - Interactive debate			
	Day III  Cross-cutting issues: drugs, and human rights, youth, children, women and communities;  9	THEMATIC SEGMENT:  - Introductory presentations by UNODC and other relevant UN entities (45 min.)  - Interactive discussion (5 minutes each)  - Interactive debate			
	<ul> <li>Day IV</li> <li>Preparations for the ministerial segment to be held during the 62nd session of the CND:</li> <li>The road ahead<sup>10</sup>: towards a one-track approach<sup>11</sup> in implementing beyond 2019 the commitments made by the international community to address and counter the world drug problem<sup>12</sup>, and in strengthening and streamlining its existing data collection systems<sup>13</sup>;</li> <li>Outstanding issues and organizational arrangements;</li> </ul>	ORGANIZATIONAL SEGMENT: - General debate			

<sup>&</sup>lt;sup>1</sup> 2009 PD and PoA, Part I.

<sup>&</sup>lt;sup>2</sup> UNGASS 2016 outcome document, Chapter 1.

<sup>&</sup>lt;sup>3</sup> 2009 PD and PoA, Part I. A.

<sup>&</sup>lt;sup>4</sup> UNGASS 2016 outcome document, Chapter 1, Sub-chapter 1.

<sup>&</sup>lt;sup>5</sup> UNGASS 2016 outcome document, Chapter 1, Sub-chapter 2.

<sup>&</sup>lt;sup>6</sup> 2009 PD and PoA, OP. 36 (b).

<sup>&</sup>lt;sup>7</sup> One expert nominated by each of the regional groups and one by the VNGOC.

<sup>&</sup>lt;sup>8</sup> UNGASS 2016 outcome document, Chapter 2.

<sup>&</sup>lt;sup>9</sup> UNGASS 2016 outcome document, Chapter 4.

<sup>&</sup>lt;sup>10</sup> This work plan is without prejudice to the discussion that would take place among Member States at the ministerial segment of the Commission on Narcotic Drugs in 2019.

<sup>&</sup>lt;sup>11</sup> Bearing in mind the Background paper by the Chair of the 60th session of the CND (E/CN.7/2017/CRP.9).

<sup>&</sup>lt;sup>12</sup> in line with CND Resolution 60/1; OPs 1-4.

<sup>&</sup>lt;sup>13</sup> in line with CND Resolution 60/1; OP 7.

4th intersessional meeting				
Time and Venue	Thematic focus	Format		
22-25 October (Board Room D)	Day I Supply reduction and related measures <sup>14</sup> , including <sup>15</sup> :  Reducing the illicit supply of drugs; <sup>16</sup> Effective law enforcement and responses to drug-related crime; <sup>17</sup> Countering money-laundering and promoting judicial cooperation; <sup>18</sup> Eliminating or reducing significantly and measurably the illicit cultivation of opium poppy, coca bush and cannabis plant; <sup>19</sup> Eliminating or reducing significantly and measurably the illicit production, manufacture, marketing and distribution of, and trafficking in, psychotropic substances, including synthetic drugs; <sup>20</sup> Eliminating or reducing significantly and measurably money-laundering related to illicit drugs; <sup>21</sup> Day II  Cross-cutting issues in addressing and countering the world drug problem: evolving reality, trends and existing circumstances, emerging and persistent challenges and threats, including new psychoactive substances, in conformity with the three international drug control conventions and other relevant international instruments; <sup>22</sup> Eliminating or reducing significantly and measurably the diversion of and illicit trafficking in precursors; <sup>23</sup> Day III  Alternative development; regional, interregional and international cooperation on development-oriented balanced drug control policy; addressing socioeconomic issues; <sup>24</sup> International cooperation on eradicating the illicit cultivation of crops used for the production of narcotic drugs and psychotropic substances and on alternative development; <sup>25</sup> Crop control strategies, including inter alia: alternative development and, where appropriate preventive alternative development programmes; eradication; law enforcement measures; <sup>26</sup>	THEMATIC SEGMENT:  - Introductory presentations by UNODC and other relevant UN entities (45 min.)  - Interactive discussion (5 minutes each)  - Interactive debate  THEMATIC SEGMENT:  - Introductory presentations by UNODC and other relevant UN entities (45 min.)  - Interactive discussion (5 minutes each)  - Interactive debate  THEMATIC SEGMENT:  - Introductory presentations by UNODC and other relevant UN entities (45 min.)  - Interactive discussion (5 minutes each)  - Interactive discussion (5 minutes each)  - Interactive debate		
	<ul> <li>Day IV</li> <li>Preparations for the ministerial segment to be held during the 62nd session of the CND:</li> <li>The road ahead<sup>27</sup>: towards a one-track approach<sup>28</sup> in implementing beyond 2019 the commitments made by the international community to address and counter the world drug problem<sup>29</sup>, and in strengthening and streamlining its existing data collection systems<sup>30</sup>;</li> <li>Outstanding issues and organizational arrangements;</li> </ul>	ORGANIZATIONAL SEGMENT: - General debate		

<sup>&</sup>lt;sup>14</sup> 2009 PD and PoA, Part II.

<sup>&</sup>lt;sup>15</sup> UNGASS 2016 outcome document, Chapter 3.

<sup>&</sup>lt;sup>16</sup> 2009 PD and PoA, Part II. B.

<sup>&</sup>lt;sup>17</sup> UNGASS 2016 outcome document, Chapter 3.

<sup>&</sup>lt;sup>18</sup> 2009 PD and PoA, Part II. B.

<sup>&</sup>lt;sup>19</sup> 2009 PD and PoA, OP. 36 (a).

<sup>&</sup>lt;sup>20</sup> 2009 PD and PoA, OP. 36 (c).

<sup>&</sup>lt;sup>21</sup> 2009 PD and PoA, OP. 36 (e).

<sup>&</sup>lt;sup>22</sup>UNGASS 2016 outcome document, Chapter 5.

<sup>&</sup>lt;sup>23</sup> 2009 PD and PoA, OP. 36 (d).

<sup>&</sup>lt;sup>24</sup> UNGASS 2016 outcome document, Chapter 7.

<sup>&</sup>lt;sup>25</sup> 2009 PD and PoA, Part II. D.

<sup>&</sup>lt;sup>26</sup> 2009 PD OP 24 (b).

<sup>&</sup>lt;sup>27</sup> This work plan is without prejudice to the discussion that would take place among Member States at the ministerial segment of the Commission on Narcotic Drugs in 2019.

<sup>&</sup>lt;sup>28</sup> Bearing in mind the Background paper by the Chair of the 60th session of the CND (E/CN.7/2017/CRP.9).

<sup>&</sup>lt;sup>29</sup> in line with CND Resolution 60/1; OPs 1-4.

<sup>&</sup>lt;sup>30</sup> in line with CND Resolution 60/1; OP 7.

## 5th intersessional meeting

Time and Venue	Thematic focus	Format
7-9 November (Board Room D)	Day I Implementation of the international drug control treaties <sup>31</sup>	NORMATIVE SEGMENT: - Briefing by the President of INCB - Discussion
	<ul> <li>Day I         <ul> <li>Strengthening international cooperation based on the principle of common and shared responsibility;<sup>32</sup></li> <li>Enhancing international cooperation, including technical assistance, to assist the States most affected by the illicit transit of drugs, especially developing countries;<sup>33</sup></li> <li>Strengthening cooperation efforts at the bilateral, regional and global levels to reduce demand for synthetic opioids for non-medical use and to counter illicit trafficking in synthetic opioids;<sup>34</sup></li> <li>Cooperation and collaboration between the Commission on Narcotic Drugs and the United Nations Office on Drugs and Crime, as well as WHO, INCB and with all relevant United Nations entities and international financial institutions, within their respective mandates;</li> </ul> </li> </ul>	THEMATIC SEGMENT:  - Introductory presentations by UNODC and other relevant UN entities (45 min.)  - Interactive discussion (5 minutes each)  - Interactive debate
	Day II  - Taking stock of the implementation of the commitments made to jointly address and counter the world drug problem, in particular in light of the decision to establish 2019 as a target date for the goals set in paragraph 36 of the Political Declaration;	THEMATIC SEGMENT:  - Introductory presentations by UNODC and other relevant UN entities (45 min.)  - Interactive discussion (5 minutes each)  - Interactive debate
	<ul> <li>Day III</li> <li>Preparations for the ministerial segment to be held during the 62nd session of the CND:</li> <li>Consideration of an outline for the reconvened 61st session: The road ahead<sup>35</sup>: towards a one-track approach<sup>36</sup> in implementing beyond 2019 the commitments made by the international community to address and counter the world drug problem <sup>37</sup>, and in strengthening and streamlining its existing data collection systems<sup>38</sup>;</li> <li>Organizational arrangements;</li> </ul>	ORGANIZATIONAL SEGMENT: - General debate

<sup>&</sup>lt;sup>31</sup> Agenda item 5, agenda of the 61<sup>st</sup> session of the CND.

<sup>&</sup>lt;sup>32</sup> UNGASS 2016 outcome document, Chapter 6.

<sup>&</sup>lt;sup>33</sup> CND resolution 60/2.

<sup>&</sup>lt;sup>34</sup> CND resolution 61/8.

<sup>&</sup>lt;sup>35</sup> This work plan is without prejudice to the discussion that would take place among Member States at the ministerial segment of the Commission on Narcotic Drugs in 2019.

<sup>&</sup>lt;sup>36</sup> Bearing in mind the Background paper by the Chair of the 60th session of the CND (E/CN.7/2017/CRP.9).

<sup>&</sup>lt;sup>37</sup> in line with CND Resolution 60/1; OPs 1-4.

<sup>&</sup>lt;sup>38</sup> in line with CND Resolution 60/1; OP 7.